Untargeted plasma metabolomic fingerprinting highlights several biomarkers for the diagnosis and prognosis of coronavirus disease 19.
COVID-19
biomarkers
diagnostic
metabolomics (OMICS)
prognostic
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
18
07
2022
accepted:
01
09
2022
entrez:
17
10
2022
pubmed:
18
10
2022
medline:
18
10
2022
Statut:
epublish
Résumé
The COVID-19 pandemic has been a serious worldwide public health crisis since 2020 and is still challenging healthcare systems. New tools for the prognosis and diagnosis of COVID-19 patients remain important issues. Here, we studied the metabolome of plasma samples of COVID-19 patients for the identification of prognosis biomarkers. Plasma samples of eighty-six SARS-CoV-2-infected subjects and 24 healthy controls were collected during the first peak of the COVID-19 pandemic in France in 2020. Plasma metabolome fingerprinting allowed the successful discrimination of healthy controls, mild SARS-CoV-2 subjects, and moderate and severe COVID-19 patients at hospital admission. We found a strong effect of SARS-CoV-2 infection on the plasma metabolome in mild cases. Our results revealed that plasma lipids and alterations in their saturation level are important biomarkers for the detection of the infection. We also identified deoxy-fructosyl-amino acids as new putative plasma biomarkers for SARS-CoV-2 infection and COVID-19 severity. Finally, our results highlight a key role for plasma levels of tryptophan and kynurenine in the symptoms of COVID-19 patients. Our results showed that plasma metabolome profiling is an efficient tool for the diagnosis and prognosis of SARS-CoV-2 infection.
Identifiants
pubmed: 36250098
doi: 10.3389/fmed.2022.995069
pmc: PMC9556858
doi:
Types de publication
Journal Article
Langues
eng
Pagination
995069Informations de copyright
Copyright © 2022 Occelli, Guigonis, Lindenthal, Cagnard, Graslin, Brglez, Seitz-Polski, Dellamonica, Levraut and Pourcher.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Crit Care Explor. 2020 Oct 21;2(10):e0272
pubmed: 33134953
Cell Host Microbe. 2017 Dec 13;22(6):817-829.e8
pubmed: 29154144
J Lipid Res. 2021;62:100129
pubmed: 34599996
Front Med (Lausanne). 2021 Jan 27;7:603961
pubmed: 33585507
Nucleic Acids Res. 2021 Jul 2;49(W1):W388-W396
pubmed: 34019663
iScience. 2020 Oct 23;23(10):101645
pubmed: 33043283
Arch Gen Psychiatry. 1993 Jul;50(7):541-50
pubmed: 8317948
Behav Pharmacol. 2018 Apr;29(2 and 3-Spec Issue):165-180
pubmed: 29543650
Biosens Bioelectron. 2021 Jan 15;172:112752
pubmed: 33126180
Sci Rep. 2021 Nov 4;11(1):21633
pubmed: 34737330
Gut Microbes. 2022 Jan-Dec;14(1):2105637
pubmed: 35895845
AAPS J. 2021 Jan 5;23(1):14
pubmed: 33400058
J Proteome Res. 2021 May 7;20(5):2796-2811
pubmed: 33724837
Antioxidants (Basel). 2021 Dec 07;10(12):
pubmed: 34943063
EBioMedicine. 2021 Jan;63:103154
pubmed: 33279860
Annu Rev Virol. 2019 Sep 29;6(1):319-340
pubmed: 31567065
Prog Lipid Res. 2021 Apr;82:101092
pubmed: 33571544
Sci Signal. 2021 Jul 06;14(690):
pubmed: 34230210
EBioMedicine. 2018 Jul;33:218-229
pubmed: 29941340
Cell Rep Med. 2021 Aug 17;2(8):100369
pubmed: 34308390
Int J Mol Sci. 2021 Apr 30;22(9):
pubmed: 33946479
JCI Insight. 2020 Jul 23;5(14):
pubmed: 32559180
J Cancer. 2019 Jun 2;10(12):2771-2782
pubmed: 31258785
Cell Mol Biol Lett. 2020 Mar 5;25:15
pubmed: 32161622
Natl Sci Rev. 2020 Jul;7(7):1157-1168
pubmed: 34676128
CNS Neurol Disord Drug Targets. 2014;13(5):817-27
pubmed: 25012620
Int J Mol Sci. 2021 Feb 05;22(4):
pubmed: 33562472
Int J Cancer. 2020 May 1;146(9):2394-2405
pubmed: 31276202
Int J Infect Dis. 2022 Jan;114:79-84
pubmed: 34653660
Biosci Rep. 2021 Mar 26;41(3):
pubmed: 33635316
Arch Med Res. 2021 Jan;52(1):107-120
pubmed: 32981754
Br J Pharmacol. 2018 Aug;175(16):3239-3250
pubmed: 29105727
Acta Biomed. 2020 May 11;91(2):118-136
pubmed: 32420936
Cancer Epidemiol. 2022 Feb;76:102075
pubmed: 34871928
Cell Rep. 2022 Jan 18;38(3):110271
pubmed: 35026155
J Microbiol Immunol Infect. 2021 Feb;54(1):12-16
pubmed: 32425996
Rev Med Virol. 2020 May;30(3):e2109
pubmed: 32314850
Cells. 2022 Jun 14;11(12):
pubmed: 35741045
Cell. 2020 Jul 9;182(1):59-72.e15
pubmed: 32492406
Biosci Rep. 2021 Aug 27;41(8):
pubmed: 34313294
BMC Bioinformatics. 2010 Jul 23;11:395
pubmed: 20650010
Cell Metab. 2020 Aug 4;32(2):188-202.e5
pubmed: 32610096
FEBS J. 2020 Sep;287(17):3633-3650
pubmed: 32446285
PLoS One. 2012;7(12):e52010
pubmed: 23284853